SEC Form 4 · accession 0001209191-18-047467

ARENA PHARMACEUTICALS INC · ARNA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, General Counsel & Sec

Period of report

Aug 15, 2018

Accepted (ET)

Aug 17, 2018 · 5:17 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001080709

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Aug 15, 2018	M	29,005	$18.10	A	48,695	D
Common Stock^F2	Aug 15, 2018	S	25,062	$35.9041	D	23,633	D
Common Stock^F3	Aug 15, 2018	S	3,943	$36.6919	D	19,690	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F4	$18.10	Aug 15, 2018	M	29,005	D	—	Mar 19, 2022	Common Stock	29,005	5,525	D

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.55 to $36.52, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
F3The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.58 to $36.83, inclusive.
F4The options vested in four equal annual installments on March 19, 2013, 2014, 2015 and 2016, and were immediately exercisable once vested.